Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease

BMB Reports

Volumn 50, Issue 9, 2017, Pages 460-460

  Jo, Hyo Sang ^a   Eum, Won Sik ^a   Park, Eun Young ^b   Ko, Je Young ^b   Kim, Do Yeon ^b   Kim, Dae Won ^c   Shin, Min Jea ^a   Son, Ora ^a   Cho, Su Bin ^a   Park, Jung Hwan ^a   Lee, Chi Hern ^a   Yeo, Eun Ji ^a   Yeo, Hyeon Ji ^a   Choi, Yeon Joo ^a   Youn, Jong Kyu ^a   Cho, Sung Woo ^d   Park, Jinseu ^a   Park, Jong Hoon ^b   Choi, Soo Young ^a  

^a Hallym University   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c Gangneung Wonju National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

3D culture; Cyst formation; PEP 1 FK506BP; Polycystic kidney diseases; Protein therapy

Indexed keywords

FK 506 BINDING PROTEIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CYST; DISEASE MODEL; GENETICS; HUMAN; KIDNEY POLYCYSTIC DISEASE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CYSTS; DISEASE MODELS, ANIMAL; HUMANS; MICROSCOPY, CONFOCAL; POLYCYSTIC KIDNEY DISEASES; SIGNAL TRANSDUCTION; TACROLIMUS BINDING PROTEIN 1A; TOR SERINE-THREONINE KINASES;

EID: 85030172331     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2017.50.9.090     Document Type: Article

References (53)

1. Wilson PD and Goilav B (2007) Cystic disease of the kidney. Annu Rev Patho 2, 341-368
2. Pei Y and Watnick T (2010) Diagnosis and screening of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17, 140-152
3. Harris PC and Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60, 321-337
4. Ye M, Grant M, Sharma M et al (1992) Cyst fluid from human autosomal dominant polycystic kidneys promotes cyst formation and expansion by renal epithelial cells in vitro. J Am Soc Nephrol 3, 984-994
5. Yoder BK, Mulroy S, Eustace H, Boucher C and Sandford R (2006) Molecular pathogenesis of autosomal dominant polycystic kidney disease. Expert Rev Mol Med 8, 1-22
6. Al-Bhalal L and Akhtar M (2008) Molecular basis of autosomal recessive polycystic kidney disease (ARPKD). Adv Anat Patho 15, 54-58
7. Gardner KD Jr, Burnside JS, Elzinga LW and Locksley RM (1991) Cytokines in fluids from polycystic kidneys. Kidney Int 39, 718-724
8. Park EY, Woo YM and Park JH (2011) Polycystic kidney disease and therapeutic approaches. BMB Rep 44, 359-368
9. Harada H, Furuya M, Ishikura H et al (2002) Expression of matrix metallo proteinase in the fluids of renal cystic lesions. J Urol 168, 19-22
10. Liu B, Li C, Liu Z, Dai Z and Tao Y (2012) Increasing extracellular matrix collagen level and MMP activity induces cyst development in polycystic kidney disease. BMC Nephrol 13, 109
11. Candiano G, Gusmano R, Altieri P et al (1992) Extracellular matrix formation by epithelial cells from human polycystic kidney cysts in culture. Virchows Arch B Cell Pathol Incl Mol Pathol 63, 1-9
12. Lee EL, Song SA, Mun HW et al (2014) Blockage of interleukin-8 receptor signaling inhibits cyst development in vitro, via suppression of cell proliferation in autosomal polycystic kidney disease. Nephrol 19, 471-478
13. Canaud G, Knebelmann B, Harris PC et al (2010) Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level? Am J Transplant 10, 1701-1706
14. Zafar I, Ravichandran K, Belibi FA, Doctor RB and Edelstein CL (2010) Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int 78, 754-761
15. Wahl PR, Le Hir M, Vogetseder A et al (2007) Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephro 12, 357-363
16. Ibraghimov-Beskrovnaya O and Natoli TA (2011) mTOR signaling in polycystic kidney disease. Trends Mol Med 17, 625-633
17. Fukuda R, Hirota K, Fan F et al (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277, 38205-38211
18. Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/ AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60, 1541-1545
19. Bae WY, Choi JS, Kim JE and Jeong JW (2015) Cinnamic aldehyde suppresses hypoxia-induced angiogenesis via inhibition of hypoxia-inducible factor-1alpha expression during tumor progression. Biochem Pharmacol 98, 41-50
20. Mi C, Ma J, Wang KS et al (2017) Imperatori suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways. J Ethnopharmacol 203, 27-38
21. Kang CB, Hong Y, Dhe-Paganon S and Yoon HS (2008) FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 16, 318-325
22. Harrar Y, Bellini C and Faure JD (2001) FKBPs: at the crossroads of folding and transduction. Trends Plant Sci 6, 426-431
23. Pong K and Zaleska MM (2003) Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord 2, 349-356
24. Lopez-Ilasaca M, Schiene C, Kullertz G et al (1998) Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J Biol Chem 273, 9430-9434
25. Costantini LC, Cole D, Chaturvedi P and Isacson O (2001) Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease. Eur J Neurosci 13, 1085-1092
26. Guo X, Dawson VL and Dawson TM (2001) Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 13, 1683-1693
27. Ross DT, Guo H, Howorth P et al (2001) The small molecule FKBP ligand GPI 1046 induces partial striatal re-innervation after intranigral 6-hydroxydopamine lesion in rats. Neurosci Lett 297, 113-116
28. Christner C, Herdegen T and Fischer G (2001) FKBP ligands as novel therapeutics for neurological disorders. Mini Rev Med Chem 1, 377-397
29. Avramut M and Achim CL (2002) Immunophilins and their ligands: Insights into survival and growth of human neurons. Physiol Behav 77, 463-468
30. Dunlop EA and Tee AR (2009) Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. Cell Signal 21, 827-835
31. Garcia JA and Danielpour D (2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7, 1347-1354
32. Long C, Cook LG, Hamilton SL, Wu GY and Mitchell BM (2007) FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension 49, 569-576
33. Raagel H, Saalik P and Pooga M (2010) Peptide-mediated protein delivery-which pathways are penetrable? Biochim Biophy Acta 1798, 2240-2248
34. Liu Y, Wang S, Luo S et al (2016) Intravenous PEP-1-GDNF is protective after focal cerebral ischemia in rats. Neurosci Lett 617, 150-155
35. Kim SY, Sohn EJ, Kim DW et al (2011) Transduced PEP-1-K506BP ameliorates atopic dermatitis in NC/Nga mice. J Invest Dermatol 131, 1477-1485
36. Kim DW, Lee SH, Shin MJ et al (2015) PEP-1-FK506BP inhibits alkali burn-induced corneal inflammation on the rat model of corneal alkali injury. BMB Rep 48, 618-623
37. Liu Y, Wang S, Luo S et al (2016) Intravenous PEP-1-GDNF is protective after focal cerebral ischemia in rats. Neurosci Lett 617, 150-155
38. Tan LG, Xiao JH, Yu DL et al (2015) PEP-1-SOD1 fusion proteins block cardiac myofibroblast activation and angiotensin II-induced collagen production. BMC Cardiovasc Disord 15, 116
39. Hwang HS, Park IY, Kim DW et al (2015) PEP-1-FK506BP12 inhibits matrix metalloproteinase expression in human articular chondrocytes and in a mouse carrageenan-induced arthritis model. BMB Rep 48, 407-412
40. Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149, 274-293
41. Novalic Z, van der Wal AM, Leonhard WN et al (2012) Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 23, 842-853
42. Serra AL, Poster D, Kistler AD et al (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363, 820-829
43. Walz G, Budde K, Mannaa M et al (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363, 830-840
44. Shillingford JM, Piontek KB, Germino GG and Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21, 489-497
45. Foster DA and Toschi A (2009) Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 8, 1026-1029
46. Chang ES, Park EY, Woo YM et al (2015) Restoring multidrug resistance-associated protein 3 attenuates cell proliferation in the polycystic kidney. Am J Physiol Renal Physiol 308, F1004-F1011
47. Okada H, Ban S, Nagao S et al (2000) Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int 58, 587-597
48. Ramasubbu K, Gretz N and Bachmann S (1998) Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. J Am Soc Nephrol 9, 937-945
49. Rankin CA, Itoh Y, Tian C et al (1999) Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease. J Am Soc Nephrol 10, 210-217
50. Watnick T and Germino GG (2010) mTOR inhibitor in polycystic kidney disease. N Egn J Med 363, 879-881
51. Bradford MA (1976) Rapid and sensitive method for the quantitation of microgram quantities utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254
52. Jo HS, Yeo HJ, Cha HJ et al (2016) Transduced Tat-DJ-1 protein inhibits cytokines-induced pancreatic RINm5F cell death. BMB Rep 49, 297-302
53. Jo HS, Kim DS, Ahn EH et al (2016) Protective effects of Tat-NQO1 against oxidative stress-induced HT-22 cell damage, and ischemic injury in animals. BMB Rep 49, 617-622